Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains

Author:

Bouzidi Hawa Sophia,Driouich Jean-SélimORCID,Klitting RaphaëlleORCID,Bernadin OrnéllieORCID,Piorkowski Géraldine,Amaral Rayane,Fraisse Laurent,Mowbray Charles E.,Scandale Ivan,Escudié FannyORCID,Chatelain EricORCID,de Lamballerie Xavier,Nougairède Antoine,Touret FranckORCID

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference44 articles.

1. Remdesivir for the treatment of Covid-19 — final report;Beigel;N. Engl. J. Med.,2020

2. Permissive secondary mutations enable the Evolution of Influenza Oseltamivir resistance;Bloom;Science,2010

3. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19;Boras;Nat. Commun.,2021

4. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model;Driouich;Nat. Commun.,2021

5. Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2;Driouich;EBioMedicine,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3